A federal outside panel voted Thursday to loosen rules on seven peptides, including BPC-157 and TB-500. The vote was tight. It is not final. The FDA has given no word on whether it will adopt the suggestion. The move came after weeks of community hearings. Wellness backers pressed firmly for wider access. RFK Jr. was among them. Critics say these compounds have insufficient safety data or help for most uses. The call could reshape how the agency handles a part of the wellness market that is scaling quickly. Regulators are watching to see if the agency adopts the plan. A representative for the agency offered no clear schedule for a response. Supporters argue the change would open up access to products users find useful. Health groups warn that looser rules could invite misuse across a wide-open market. The committee vote only plants the seed for a shift, and the ultimate call rests with the federal agency.